Vaxart (STU:NB11) Receivables Turnover : 1.23 (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Vaxart Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Vaxart's Revenue for the three months ended in Mar. 2024 was €2.01 Mil. Vaxart's average Accounts Receivable for the three months ended in Mar. 2024 was €1.64 Mil. Hence, Vaxart's Receivables Turnover for the three months ended in Mar. 2024 was 1.23.

Vaxart Receivables Turnover Historical Data

The historical data trend for Vaxart's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxart Receivables Turnover Chart

Vaxart Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

3.67

1.88

4.67

2.46

4.87

Vaxart Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Receivables Turnover	Get a 7-Day Free Trial															1.95	9.15	1.97	3.85	1.23

Competitive Comparison of Vaxart's Receivables Turnover

For the Biotechnology subindustry, Vaxart's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxart's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxart's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Vaxart's Receivables Turnover falls into.

Vaxart Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Vaxart's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	6.767	/ (	(0.019	+	2.758)	/	2 )
=	6.767	/	1.3885
=	4.87

Vaxart's Receivables Turnover for the quarter that ended in Mar. 2024 is calculated as

	Receivables Turnover (Q: Mar. 2024 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2024 )	/ (	(Accounts Receivable (Q: Dec. 2023 )	+	Accounts Receivable (Q: Mar. 2024 ))	/	count )
=	2.007	/ (	(2.758	+	0.512)	/	2 )
=	2.007	/	1.635
=	1.23

Vaxart (STU:NB11) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Vaxart Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Vaxart's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxart (STU:NB11) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxart Inc (STU:NB11) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

VXRT:USA VXRT:Mexico

Address

170 Harbor Way, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.vaxart.com

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Vaxart (STU:NB11) Headlines

No Headlines